Government, academia, pharmaceutical and diagnostic companies are collaborating to create the National Cancer Institute’s Blood Profiling Atlas – an open access liquid biopsy database. The database pulls together scientific data for use by researchers in an effort to reduce development time of new blood profiling diagnostic technologies to help cancer patients.
“Liquid biopsies are going to be critical in the future to both identify specific patients for targeted therapies and to follow their treatment to better determine response to therapy,” said Lilly medical fellow Dr. Andrew Schade in a statement. “We hope knowledge gained from our research efforts in this area will help to accelerate the development of safe and effective blood profiling diagnostic technologies that help people with cancer.”
Check out this article by Stacy Lawrence, FierceBiotech, for additional details on this Cancer Moonshot update.